PARPis also reportedly decrease the tumor-infiltrating cytotoxic CD8+ T-cell population, while addition of PD-L1 blockade increases the cytotoxic CD8+ T-cell population, thereby re-sensitizing PARPi-treated tumor cells to T-cell killing in TNBC [97]. The gene discussed is CD8A; the disease is neoplasm.